Expertise in
6
conditions

Dr. Rachel M. Presti

Infectious Disease
Office
620 S Taylor Ave Ste 100, 
Saint Louis, MO 
Accepting New Patients
Expertise in
6
conditions
Office
620 S Taylor Ave Ste 100, 
Saint Louis, MO 

Overview

Rachel Presti is an Infectious Disease provider practicing medicine in Saint Louis, Missouri.

Dr. Presti is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

She is actively involved in clinical research, co-authoring 91 peer reviewed articles and participating in 10 clinical trials. Dr. Presti is currently accepting new patients.

Specialties

Infectious Disease

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes Jewish Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Office
620 S Taylor Ave Ste 100, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Phase: Phase 2
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Doravirine, Tenofovir alafenamide, Emtricitabine, Lamivudine, Integrase strand transfer inhibitors, Tenofovir disproxil fumarate
Study Phase: Phase 4
Washington University (WU) 321: Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine: Fine Needle Aspiration (FNA) and Bone Marrow Aspiration (BMA)
Washington University (WU) 321: Analysis of Antigen Specific B Cell Responses to Immunization With Influenza Virus Vaccine: Fine Needle Aspiration (FNA) and Bone Marrow Aspiration (BMA)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: Influenza Vaccine
Study Phase: Early Phase 1
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Open-label, Randomized Controlled Trial of Hydroxychloroquine, Hydroxychloroquine Plus Azithromycin, Chloroquine Alone, Chloroquine Plus Azithromycin in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infection
Open-label, Randomized Controlled Trial of Hydroxychloroquine, Hydroxychloroquine Plus Azithromycin, Chloroquine Alone, Chloroquine Plus Azithromycin in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infection
Enrollment Status: Terminated
Publish Date: April 25, 2024
Intervention Type: Drug
Study Phase: Phase 3
WU 360: Assessing the Impact of Integrase Strand Transfer Inhibitors (INSTI) to Protease Inhibitor (PI) Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY): a Sub-study of DEFINE
WU 360: Assessing the Impact of Integrase Strand Transfer Inhibitors (INSTI) to Protease Inhibitor (PI) Switch on Insulin Sensitivity and Fat Metabolism (ADIPOSITY): a Sub-study of DEFINE
Enrollment Status: Completed
Publish Date: August 03, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
IMPAACT P1107: Cord Blood Transplantation With CCR5Δ32 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence
IMPAACT P1107: Cord Blood Transplantation With CCR5Δ32 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence
Enrollment Status: Completed
Publish Date: March 01, 2023
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance
Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance
Enrollment Status: Completed
Publish Date: January 27, 2020
Intervention Type: Drug, Other
Study Phase: Not Applicable
Effect of CCR5 Inhibition by Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant for Any Indication and Its Observed Effect on Graft Versus Host Disease and HIV-1 Persistence
Effect of CCR5 Inhibition by Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant for Any Indication and Its Observed Effect on Graft Versus Host Disease and HIV-1 Persistence
Enrollment Status: Withdrawn
Publish Date: November 07, 2018
Intervention Type: Procedure, Other
Study Phase: Phase 1
View 9 Less Clinical Trials

91 Total Publications

LIMIT Trial: Lidocaine with Intramuscular Injection of Benzathine Penicillin G for Treponema pallidum Treatment.
LIMIT Trial: Lidocaine with Intramuscular Injection of Benzathine Penicillin G for Treponema pallidum Treatment.
Journal: Sexually transmitted diseases
Published: August 24, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Gary J. Weil
Infectious Disease
Expertise in
9
conditions
Dr. Gary J. Weil
Infectious Disease
Referral may be required

Washington University School

216 S Kingshighway Blvd, 
Saint Louis, MO 
 (0.9 miles away)
314-362-4485
Languages Spoken:
English
See accepted insurances

Gary Weil is an Infectious Disease provider practicing medicine in Saint Louis, Missouri. Dr. Weil is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Lymphatic Filariasis, Spirurida Infections, Secernentea Infections, and Helminthiasis.

Expertise in
5
conditions
Dr. Philip J. Budge
Infectious Disease
Expertise in
5
conditions
Dr. Philip J. Budge
Infectious Disease
Referral may be required

Barnes-Jewish Hospital

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (0.7 miles away)
314-747-3000
Languages Spoken:
English
See accepted insurances

Philip Budge is an Infectious Disease provider practicing medicine in Saint Louis, Missouri. Dr. Budge is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Lymphatic Filariasis, Spirurida Infections, Loiasis, and Secernentea Infections.

Expertise in
8
conditions
Dr. Andrej Spec
Infectious Disease
Expertise in
8
conditions
Dr. Andrej Spec
Infectious Disease
Referral may be required

Washington University

660 S Euclid Ave, 
Saint Louis, MO 
 (0.7 miles away)
314-362-9098
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrej Spec is an Infectious Disease provider practicing medicine in Saint Louis, Missouri. Dr. Spec is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Cryptococcosis, Blastomycosis, Coccidioidomycosis, and Acute Pulmonary Histoplasmosis. Dr. Spec is currently accepting new patients.

Frequently Asked Questions about Dr. Rachel M. Presti

How do I make an appointment with Dr. Rachel M. Presti?

You can book an appointment with Dr. Rachel M. Presti by calling their office at 314-362-9098. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rachel M. Presti a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rachel M. Presti is classified as an Distinguished expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rachel M. Presti specialize in?

While Dr. Rachel M. Presti is a Infectious Disease, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dementia Complex. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Rachel M. Presti participate in research or clinical trials?

Yes. Dr. Rachel M. Presti has published 91 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Rachel M. Presti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rachel M. Presti accept my insurance?

Dr. Rachel M. Presti accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-362-9098 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Presti's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile